---
title: "Bio-Thera Solutions, Ltd. (688177.SH) — Company Overview"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688177.SH/overview.md"
symbol: "688177.SH"
name: "Bio-Thera Solutions, Ltd."
parent: "https://longbridge.com/en/quote/688177.SH.md"
datetime: "2026-04-06T07:49:04.694Z"
locales:
  - [en](https://longbridge.com/en/quote/688177.SH/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688177.SH/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688177.SH/overview.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/688177.SH/overview.md) | [繁體中文](https://longbridge.com/zh-HK/quote/688177.SH/overview.md)


# Bio-Thera Solutions, Ltd. (688177.SH) — Company Overview

## Basic Information

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Address | No.18, Helix 2 Road, International Biological Island, Guangzhou, Guangdong |
| Website | [www.bio-thera.com](https://www.bio-thera.com) |

## Company Profile

Bio-Thera Solutions, Ltd., a biopharmaceutical company, researches and develops novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs in China and internationally. It offers QLETLI for the treatment of ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn’s disease, and uveitis; POBEVCY to treat patients with metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer; TOFIDENCE for the treatment of rheumatoid arthritis, polyarticular and systemic juvenile idiopathic arthritis, and cytokine release syndrome; and BETAGRIN for the treatment of acute coronary syndromes. The company also develops BAT2206, a biosimilar drug candidate used to treat psoriasis, Crohn’s disease, and ulcerative colitis; BAT2306 to treat plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis; and BAT4406F, BAT6026, BAT2606, and BAT2506 for treatment of various autoimmune diseases. In addition, it develops BAT4306F, BAT1308, BAT1006, BAT4706, BAT6026, BAT7104, BAT7104, BAT8006, BAT8010, BAT8008, and BAT8007 for treatment of oncology; BAT2094 and BAT6024 to treat cardiovascular diseases; and BAT5906 that is in Phase III clinical trial for the treatment for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).

## Major Shareholders

| Name | Ratio | Report Date |
|------|-------|-------------|
| 广州七喜集团有限公司 | 38.64% | 2025-10-29 |
| Therabio International Limited | 11.39% | 2025-10-29 |
| 新余兴奥企业管理合伙企业(有限合伙) | 5.60% | 2025-10-29 |
| 广州中科粤创孵化器投资管理有限公司-广州中科粤创三号创业投资合伙企业(有限合伙) | 5.15% | 2025-10-29 |
| 新余臻合企业管理合伙企业(有限合伙) | 3.86% | 2025-10-29 |
| 新余市启恒管理咨询合伙企业(有限合伙) | 3.10% | 2025-10-29 |
| 易良昱 | 2.84% | 2025-10-29 |
| 广州返湾湖投资合伙企业(有限合伙) | 1.79% | 2025-10-29 |
| SHENGFENG LI | 1.57% | 2025-10-29 |
| 香港中央结算有限公司 | 1.45% | 2025-10-29 |

## Business Breakdown

| Segment | Revenue | Ratio |
|---------|---------|-------|
| Biopharmaceutical | 933685000 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "Bio-Thera Solutions, Ltd. Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Biopharmaceutical",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```


---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**